Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Dr. Lal Pathlabs

₹2431.7 4.4 | 0.2%

Market Cap ₹20299 Cr.

Stock P/E 61.5

P/B 10.9

Current Price ₹2431.7

Book Value ₹ 222.1

Face Value 10

52W High ₹2766.9

Dividend Yield 0.49%

52W Low ₹ 1762.7

Overview Inc. Year: 1995Industry: Hospital & Healthcare Services

Dr. Lal PathLabs Ltd is an India-based organisation, that is engaged in offering diagnostic and associated healthcare assessments and offerings. It has a community that have a National Reference Laboratory in New Delhi, a Reference Laboratory in Kolkata and approximately 229 other clinical laboratories. The Company is engaged specially within the enterprise of strolling laboratories for carrying out pathological investigations of diverse branches of biochemistry, haematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and different pathological and radiological investigations. The Company offers various tests by condition, which incorporates allergic reaction, diabetes, health checkups, viral infections, fever, heart sicknesses, high blood pressure, cancer, abortions, anaemia, arthritis, breast cancer, diphtheria, disease of liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular sickness and viral infections.

Read More..

Dr. Lal Pathlabs Share Price

New

| |

Volume
Price

Quarterly Price

Show Value Show %

Dr. Lal Pathlabs Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 498 497 486 503 534 489 491 541 601 539
Other Income 14 12 12 8 9 11 14 14 18 18
Total Income 513 509 498 511 543 500 505 555 619 557
Total Expenditure 357 388 364 385 390 376 375 395 424 398
Operating Profit 156 121 133 126 153 124 130 161 196 159
Interest 5 9 12 9 11 9 9 8 8 7
Depreciation 21 31 38 36 39 38 38 35 36 36
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 131 82 84 81 103 77 83 118 152 116
Provision for Tax 34 23 21 23 30 23 26 34 42 34
Profit After Tax 96 58 62 58 72 54 57 84 111 82
Adjustments -1 -1 -1 -1 -1 -1 -0 -1 -1 -1
Profit After Adjustments 95 57 61 58 72 53 57 83 109 81
Adjusted Earnings Per Share 11.4 6.9 7.4 6.9 8.6 6.3 6.8 9.9 13.1 9.7

Dr. Lal Pathlabs Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 452 558 660 791 912 1057 1203 1330 1581 2087 2017 2172
Other Income 3 8 13 22 28 31 46 55 51 53 42 64
Total Income 455 566 673 813 940 1088 1249 1385 1633 2140 2059 2236
Total Expenditure 354 419 504 584 675 793 910 987 1145 1527 1527 1592
Operating Profit 101 147 168 229 265 295 340 399 488 613 532 646
Interest 0 0 0 0 1 1 1 15 16 30 38 32
Depreciation 20 27 28 28 28 33 38 73 77 108 150 145
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 80 119 140 201 237 261 301 311 394 475 344 469
Provision for Tax 25 39 43 67 81 90 100 83 98 125 103 136
Profit After Tax 56 80 96 133 156 172 200 228 296 350 241 334
Adjustments -1 -1 -1 -1 -1 -1 -1 -2 -5 -5 -2 -3
Profit After Adjustments 55 80 96 132 155 171 199 226 292 345 239 330
Adjusted Earnings Per Share 0 0 0 16 18.6 20.5 23.9 27.1 35 41.4 28.6 39.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -3% 15% 14% 16%
Operating Profit CAGR -13% 10% 13% 18%
PAT CAGR -31% 2% 7% 16%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 25% 1% 19% NA%
ROE Average 16% 23% 23% 30%
ROCE Average 20% 30% 31% 41%

Dr. Lal Pathlabs Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 162 231 341 507 596 788 945 1033 1245 1502 1666
Minority's Interest 2 2 2 3 2 4 5 21 31 35 33
Borrowings 0 0 0 0 0 0 0 0 0 167 83
Other Non-Current Liabilities 3 1 -5 12 -6 -9 -20 70 83 106 93
Total Current Liabilities 89 97 112 91 85 116 138 227 274 500 470
Total Liabilities 256 332 450 613 676 899 1069 1351 1633 2310 2345
Fixed Assets 127 140 150 166 152 208 209 413 447 1369 1305
Other Non-Current Assets 13 22 18 24 57 68 47 46 41 66 67
Total Current Assets 117 170 282 424 467 623 814 893 1145 875 973
Total Assets 256 332 450 613 676 899 1069 1351 1633 2310 2345

Dr. Lal Pathlabs Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 8 17 16 23 27 29 66 129 197 244 378
Cash Flow from Operating Activities 88 98 122 159 171 197 219 284 398 447 456
Cash Flow from Investing Activities -65 -90 -113 -163 -137 -172 -100 -26 -212 -449 -287
Cash Flow from Financing Activities -15 -10 -1 0 -32 13 -55 -190 -139 136 -283
Net Cash Inflow / Outflow 8 -2 8 -5 2 37 64 67 48 134 -114
Closing Cash & Cash Equivalent 17 16 23 19 29 66 129 197 244 378 264

Dr. Lal Pathlabs Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0 0 0 15.99 18.61 20.49 23.9 27.11 34.99 41.37 28.65
CEPS(Rs) 14.17 20.03 22.81 19.54 22.05 24.58 28.64 36.04 44.83 55 46.93
DPS(Rs) 15.4 1.1 1.53 2.45 3 4.5 6 12 20 12 12
Book NAV/Share(Rs) 0 0 0 61.28 70.66 92.39 110.08 119.97 144.61 173.17 192.88
Core EBITDA Margin(%) 21.62 24.83 23.52 26.24 26.03 24.98 24.4 25.83 27.59 26.86 24.29
EBIT Margin(%) 17.85 21.4 21.24 25.43 26.03 24.8 25.04 24.49 25.95 24.2 18.91
Pre Tax Margin(%) 17.76 21.37 21.18 25.36 25.96 24.72 24.97 23.34 24.94 22.75 17.05
PAT Margin (%) 12.32 14.39 14.62 16.84 17.05 16.25 16.66 17.11 18.75 16.78 11.95
Cash Profit Margin (%) 16.84 19.27 18.89 20.41 20.07 19.38 19.83 22.58 23.63 21.96 19.4
ROA(%) 25.86 27.3 24.67 25.06 24.13 21.81 20.38 18.81 19.87 17.77 10.36
ROE(%) 40.52 43.95 37.14 32.45 28.45 25.32 23.76 23.74 26.89 26.45 15.8
ROCE(%) 57.93 60.49 48.87 47.43 43.07 37.9 34.78 32.94 36.03 32.67 20.34
Receivable days 13.78 14.7 15.53 15.51 15.62 14.32 14.31 14.35 13.63 13.3 14.14
Inventory Days 6 6.64 7.18 6.64 6.49 7.81 8.47 11.73 11.49 8.31 7.81
Payable days 101.56 99.7 87.86 80.66 87.64 95.14 101.04 120.69 120.3 105.92 123.86
PER(x) 0 0 0 57.63 51.99 42.7 44.12 51.69 77.38 63.02 63.8
Price/Book(x) 0 0 0 15.04 13.69 9.47 9.58 11.68 18.72 15.06 9.48
Dividend Yield(%) 0 0 0 0.27 0.31 0.51 0.57 0.86 0.74 0.46 0.66
EV/Net Sales(x) -0.04 -0.04 -0.1 9.36 8.55 6.6 6.9 8.35 13.68 10.28 7.34
EV/Core EBITDA(x) -0.16 -0.17 -0.4 32.28 29.42 23.63 24.43 27.87 44.38 34.99 27.86
Net Sales Growth(%) 31.98 23.53 18.22 19.97 15.3 15.84 13.86 10.55 18.86 32.01 -3.38
EBIT Growth(%) 16.95 48.07 17.35 43.6 18.04 10.37 14.96 8.11 25.96 23.09 -24.51
PAT Growth(%) 23.2 44.24 20.15 38.15 16.78 10.39 16.72 13.53 30.27 18.15 -31.18
EPS Growth(%) 0 0 0 0 16.4 10.09 16.65 13.43 29.07 18.25 -30.75
Debt/Equity(x) 0 0 0 0 0 0 0 0 0 0.24 0.15
Current Ratio(x) 1.31 1.75 2.52 4.67 5.5 5.37 5.88 3.93 4.18 1.75 2.07
Quick Ratio(x) 1.23 1.64 2.39 4.51 5.29 5.14 5.68 3.68 4.02 1.65 2
Interest Cover(x) 183.69 603.05 346.2 404.57 340.29 311.72 359.22 21.28 25.65 16.74 10.16
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0.02 0.02

Dr. Lal Pathlabs Shareholding Pattern

# Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Promoter 55.23 55.23 55.23 55.05 55.05 55.05 55.03 55.01 54.61 54.6
FII 26.82 25.45 23.44 22.37 23.26 25.8 24.89 23.27 24.36 25.35
DII 5.73 6.58 6.83 6.52 6.27 6.19 6.55 8.63 9.14 9.56
Public 12.22 12.75 14.5 16.06 15.43 12.96 13.52 13.1 11.89 10.49
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 23%
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Debtor days have increased from 105.92 to 123.86days.
  • Stock is trading at 10.9 times its book value.
  • The company has delivered a poor profit growth of 6% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Dr. Lal Pathlabs News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....